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ABSTRACT 
The madurastatins are pentapeptide siderophores originally described as containing an unusual 
salicylate capped N-terminal aziridine ring. Isolation of madurastatin C1 (1) (also designated 
MBJ-0034), from Actinomadura sp. DEM31376 (itself isolated from a deep sea sediment), 
prompted structural reevaluation of the madurastatin siderophores, in line with the recent work of 
Thorson and Shaaban. NMR spectroscopy in combination with partial synthesis allowed 
confirmation of the structure of madurastatin C1 (1), as containing an N-terminal 2-(2-
hydroxyphenyl)-oxazoline in place of the originally postulated aziridine, whilst absolute 
stereochemistry was determined via Harada’s advanced Marfey’s method. Therefore this work 
further supports Thorson and Shaaban’s proposed structural revision of the madurastatin class of 
siderophores (madurastatins A1 (2), B1 (3), C1 (1) and MBJ-0036 (4)) as N-terminal 2-(2-
hydroxyphenyl)-oxazolines.  
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Siderophores are key components of the bacterial endogenous secondary metabolome, 
facilitating intracellular uptake of Fe3+ and other essential metals from the surrounding 
environment.1 Pathogenic bacteria also employ siderophores to sequester metals from the host 
organism, thus playing an important role in virulence.2 The genus Actinomadura,3 from the 
family Thermomonosporaceae, contains both environmental (predominately soil dwelling) and 
opportunistically pathogenic species and are a source of a number of bioactive secondary 
metabolites4 including the madurastatin5 and maduraferrin6 siderophores. 
As part of a program to identify new natural products from actinobacteria,7 we have 
investigated the secondary metabolite production of a marine isolate Actinomadura sp. 
DEM31376. Along with the known cyclic heptapeptide RNAP inhibitor GE23077,8 we isolated 
the siderophore madurastatin C1 (1)5b (also designated MBJ-0034).5c Spectroscopic analysis of 
isolated 1 was however not consistent with the originally reported structure. Recent work by 
Thorson and Shaaban proposed a structural revision for the madurastatins as containing a 2-(2-
hydroxyphenyl)-oxazoline moiety, based on an analysis of the NMR data pertaining to both 
related bacterial siderophores and synthetic intermediates.9 Thus as part of our investigations we 
compared isolated madurastatin C1 (1) to both aziridine and 2-(2-hydroxyphenyl)-oxazoline 
containing synthetic analogues, as well as examining the absolute stereochemistry of 
madurastatin C1 (1) via a Marfey’s analysis. 
 
RESULTS AND DISCUSSION 
Madurastatin C1 (1) was first isolated from the fermentation broth of Actinomadura sp. DSMZ 
13491 by Sosio et al. in 2012,5b and again by Shin-ya et al. in 2014 (as MBJ-0034 along with the 
related siderophore MBJ-0035 (4)),5c and was originally assigned as a linear pentapeptide 
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containing a salicylate capped N-terminal aziridine ring by spectroscopic analysis and analogy to 
the previously reported madurastatins A1 (2) and B1 (3) (Figure 1). 
 
Figure 1. Previously proposed structures of the “aziridine” containing madurastatin siderophores 
In our hands, madurastatin C1 (1) was reisolated from Actinomadura sp. DEM31376, a strain 
originally isolated from deep sea marine sediment (Canary Basin, Atlantic Ocean).10 Based on 
16S rRNA analysis, strain DEM31376 was recovered in the genus Actinomadura, forming a 
subgroup with the type strains of A. mexicana, A. citrea and A. scrupli. Although closely related 
to both A. mexicana and A. citrea (99.4% 16S rRNA gene similarity) taxonomic analysis 
suggests that strain DEM31376 may form the nucleus of a novel species within the genus 
Actinomadura (Figure 2).11 
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Figure 2. (a) Scanning electron micrograph of strain DEM31376 showing spiral chains of warty 
ornamented spores following growth on ISP3 agar, bar indicates 2 m. (b) Neighbor-joining tree 
based on nearly complete 16S rRNA gene sequences showing relationships between strain 
DEM31376 and closely related type strains of Actinomadura species. Asterisks indicate branches 
also recovered using maximum likelihood and maximum parsimony tree making methods. 
Numbers at nodes indicate bootstrap values based on neighbor joining analysis of 1000 
resampled datasets. 
Strain DEM31376 was cultivated in ISP2 media in a 20 L bioreactor. Absorption of the 
fermentation broth onto Amberlite® XAD16N beads (elution MeOH), solid phase capture on C8 
SPE cartridges (elution with 50-100% MeOH), and finally reverse phase column 
chromatography (gradient elution, H2O to MeOH, Biotage® Isolera™ SNAP C18) provided 238 
mg of 1.12 ESI-HRMS showed an [M+H]+ ion at 592.2732 m/z, confirming molecular formula 
(C26H37O9N7). MS/MS gave fragments at 462, 434, 403, 349 and 318 m/z in line with previous 
analysis,5b whilst HPLC-ESI-MS showed the presence of a related molecule at 610 m/z, formed 
via hydrolysis of the parent ion. 13C NMR revealed 26 carbon signals, six corresponding to an 
ortho-disubstituted benzene and six to carbonyl-like carbons, three of which were shown to be 
primary amides though HMBC correlations with exchangeable protons at 8.52, 7.93 and 8.11 
ppm. Thus, the remaining two degrees of unsaturation are the due to the presence of a further 
two ring systems. 1H NMR, COSY and 15N-1H HSQC revealed five amino acid spin systems, 
namely: glycine, β-alanine, a modified serine and two modified ornithines. Indirect measurement 
of the natural abundance 15N spectra by 1H-15N HMBC showed the presence of seven nitrogen 
atoms in four different chemical shift ranges indicative of three amides, two hydroxamic acids, 
one amine and an unusual imine-like nitrogen.  The role of 1 as a hexadentate siderophore was 
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confirmed through chelation with both Fe(acac)3 and Ga(acac)3, HPLC-ESI-MS showing signals 
at 645.2 and 658.2 m/z corresponding to the protonated 1:1 complexes of 1 with Fe3+ and Ga3+ 
respectively. Interestingly chelation with Fe(acac)3  gave rise to an additional compound (663.2 
m/z) demonstrating that hydrolysed 1 is also a competent ligand for Fe3+. Furthermore 1 showed 
growth reduction against Bacillus subtilis (disk diffusion assay) presumably through an 
inhibition of Fe3+uptake. 
The NMR data of 1 did however highlight a number of discrepancies with the originally 
proposed structure. In particular the 13C NMR shifts for the - and -carbons of the serine 
residue are observed at 67 and 69 ppm, highly atypical of an aryloyl substituted aziridine ring 
(shift range 25-45 ppm).13 Thorson and Shaaban recently proposed that the madurastatin 
siderophores contain a N-terminal 2-(2-hydroxyphenyl)-oxazoline ring,9 a bidentate coordination 
moiety present in a number of other mixed ligand siderophores (e.g. acinetobactin,14 the 
amamistatins,15 the amychelins,16 brasilibactin A,17 gobichelin A and B,18 nocardichelins A and 
B,19 transvalencin Z20 and the spoxazomicins A-C21), in which the corresponding 13C shifts 
typically occur from 65 to 72 ppm (Table 1). 
Table 1. Revised structure and NMR data for madurastatin C1 (DMSO-d6, 298 K, 700 MHz) 
 
position δC, type δH (J in Hz) δNc 
1 159.1, C - - 
2 116.6, CH 7.01, dd (8.3, 1.1) - 
 7 
3 134.1, CH 7.47, ddd (8.7, 7.3, 1.8) - 
4 119.1, CH 6.95, td (7.5, 1.1) - 
5 128.1, CH 7.65, dd (7.8, 1.8) - 
6 109.9, C - - 
7 165.9, C - - 
8 - - 208.2 
9 67.4, CH 5.01, dd (10.4, 7.7) - 
10 69.4, CH2 4.65, dd (10.5, 8.4) 
4.52, t (8.0) 
- 
11 170.2, C - - 
12 - 8.52, t (5.9) 109.2 
13 42.2, CH2 3.75, dd (16.5, 6.1) 
3.67, dd (16.5, 5.7) 
- 
14 168.4, C - - 
15 - 7.93, t (5.8 Hz) 112.5 
16 34.6, CH2 3.28 – 3.22, m - 
17 32.0, CH2 2.53 – 2.51, m - 
18 170.9, C - - 
19 - - 175.9 
20 47.0, CH2 3.51 – 3.42, mb - 
21 22.8, CH2 1.63 – 1.53, m - 
22 30.2, CH 1.50 – 1.45, m 
1.43 – 1.38, m 
- 
23 63.7, CH 2.87, t (6.6) - 
24 - - 29.1 
25 34.2, CH3 2.21, s - 
26 173.5, C - - 
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27 - 8.11, d (8.3) 118.8 
28 49.4, CH 4.32, ddd (10.9, 8.2, 5.3) - 
29 27.8, CH2 1.96 – 1.82, mb 
1.67 qd (12.5, 4.3) 
- 
30 20.4, CH2 1.96 – 1.82, mb - 
31 51.2, CH2 3.51 – 3.42, mb - 
32 - - 171.8 
33 165.0, C - - 
aHMBC performed at 10 Hz, bsignals overlapping, c15N shifts measured indirectly by 1H-15N 
HMBC performed at both 8 and 12 Hz, referenced against liq. NH3 
To test this hypothesis, we synthesized the salicylate containing fragment of 1 as both an 
aziridine 5 and as an oxazoline 6 for comparison. N-Trityl-L-serine methyl ester 7 was activated 
with mesyl chloride followed by base catalysed intramolecular ring closure to give methyl (S)-1-
tritylaziridine-2-carboxylate 8, confirmed by single crystal X-ray analysis.22 Trityl deprotection 
with TFA/Et3SiH in DCM
23 followed by in situ reaction with 2-(benzyloxy)benzoyl chloride 
gave the desired aziridine containing fragment 5 (Scheme 1). 
 
Scheme 1. (i) MsCl, Et3N, DCM, 0 °C to RT, 18 h, then Et3N, THF, reflux, 16 h, 70%. (ii) 
Et3SiH, Et3N, DCM, 0 °C to RT, 5 h. (iii) 2-(benzyloxy)benzoyl chloride, Et3N, -78 °C to RT, 48 
h, 35% over 2 steps. 
Synthesis of the oxazoline containing fragment 6 involved reaction of L-serine methyl ester 9 
with 2-(benzyloxy)benzoyl chloride to give amide 10. Attempted oxazoline formation with 
thionyl chloride gave only low yields of 6 alongside an unwanted chlorinated derivative 11.24 
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Treatment of 10 with diethylaminosulphur trifluoride (DAST) provided the desired oxazoline 6 
in 79% yield.25 Confirmation of the structure of 6 was given by single crystal X-ray analysis,22 
including comparison to the closely related X-ray structure of spoxazomicin C (Scheme 2).21a 
 
Scheme 2. (i) 2-(benzyloxy)benzoyl chloride, Et3N, -78 °C to RT, 18 h, 95%. (ii) DCM, DAST, 
-78 °C to RT, 2 h, 79%. 
Comparison of the 1H and 13C NMR spectra of 1, 5 and 6 confirmed the presence of an 
oxazoline in the natural product. Both the 13C NMR shifts of the ring carbons (C-2 and C-3) and 
carbonyl-like carbon (C-1) and the 1H NMR shifts for Ha, Hb and Hc of 1 align well with those of 
synthetic oxazoline 6. In addition, coupling constant analysis of 6 shows Jcis. Jtrans and Jgem of 
10.5, 7.6 and 8.8 Hz respectively,26 corresponding closely to those observed in 1 (note that in 5, 
Jcis = 5.3, Jtrans = 3.1 and Jgem = 1.3 Hz, demonstrating the small geminal coupling characteristic 
of an aziridine).27 Analysis of the literature pertaining to the madurastatin siderophores A1 and 
MBJ-0036 reveals that the 1H and 13C NMR data of these compounds also closely match those of 
oxazoline 6, suggesting that in agreement with Thorson and Shaaban,9 these structures should 
also be similarly revised as containing an N-terminal 2-(2-hydroxyphenyl)-oxazoline (Table 2). 
Table 2. 1H and 13C NMR comparison of 1 with synthetic compounds 5 and 6. 
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position 1 5 6 
1, δC 165.9 178.1 168.1 
2, δC 67.4 33.1 69.3 
3, δC 69.4 37.5 70.8 
Ha, δH (J in Hz) 5.05 dd (10.7, 8.1) 3.23 dd (5.3, 3.1) 4.97 dd (10.5, 7.6) 
Hb, δH (J in Hz) 4.69 dd (10.7, 8.5) 2.63 dd (5.3, 1.3) 4.62 dd (10.5, 8.8) 
Hc, δH (J in Hz) 4.61 t (8.3)b 2.62 dd (3.1, 1.3) 4.67 dd (8.8, 7.6) 
a(700 MHz, CD3OD), 
bsignal is an apparent triplet due to similar values of Jtrans and Jgem 
 
Finally Harada’s advanced Marfey’s method was employed to determine the absolute 
stereochemistry of madurastatin C1 (1).28 Hydrolysis of 1 with concentrated HI29 and 
derivatization with Nα-(5-fluoro-2,4-dinitrophenyl)-L-leucinamide was followed by analysis by 
HPLC-ESI-MS. Comparison to pre-prepared amino acid standards revealed the presence of D-
serine, L-N-methyl-ornithine and L-ornithine allowing absolute stereochemical determination of 
all three stereocentres (Figure 3). 
 
Figure 3. Revised structure of madurastatin C1 (1) including absolute stereochemistry. 
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In conclusion, we have confirmed Thorson and Shaaban’s revised structure of madurastatin C1 
(1) as an oxazoline containing mixed ligand N-terminal 2-(2-hydroxyphenyl)-oxazoline 
hexadentate siderophore and have determined its absolute stereochemistry. Based on NMR 
analysis, similar structural revisions should also be applied across the madurastatin family of 
natural products including madurastatin A1, B1 and MBJ-0035.5,9 
 
Supporting Information.  
The Supporting Information is available free of charge on the ACS Publications website at DOI: 
XXXX. 
Characterization details for DEM31376, isolation procedures and analysis (including 1D and 2D 
NMR spectra) for madurastatin C1 (1), experimental details for the synthesis and 
characterization of compounds 5, 6, 8 and 10, crystal data for 6, 8 and 10 (PDF). 
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